Booz Allen Hamilton's earnings may be skewed due to a large unusual item, suggesting its true earnings power could be less. Its earnings per share also decreased last year. The company has 2 warning signs that need attention.
The company's strong performance is attributed to robust demand for its consulting service from the Department of Defense and other clients, and growing headcount. The raised projections for the fiscal year ending in March reflect the company's positive outlook.
Despite lower earnings, Booz Allen Hamilton Holding still expected to see strong future growth by investors, hence a high P/E ratio. The forecasted growth beats the broader market, showing shareholder confidence in future earnings, hinting a large price drop is unlikely soon.
Substantial sale of shares by the Independent Chairman at a low price signals insiders' scepticism about the company's valuation. The high level of insider ownership aligns leadership's interests with those of shareholders.
Our Call What's next for A&D? Next RKLB Electron launch scheduled for later in August. Defense budget discussion likely on hold with Congress on recess until September. DSEI defense conference 9/12-9/15 in London. HWM plant tour/investor meeting 9/20. Positive on aero: Commercial aerospace remains one of the best multi-year growth stories in industrials, in our view, with pent-up demand for aircraft driving production higher and ...
Gainers: •$Antares Pharma(ATRS.US)$+48.7% (to be acquired by Halozyme (HALO) for $5.60 per share) •$Sierra Oncology(SRRA.US)$+37.9% (acquired by GSK for $55 per share) •$Amryt Pharma(AMYT.US)$+11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients) •$BriaCell Therapeutics(BCTX.US)$+6% (presents development details of...
博思艾倫諮詢公司股票討論區
專欄A&D Weekly: Next Electron Launch; Budget on Hold Until September
What's next for A&D? Next RKLB Electron launch scheduled for later in August. Defense budget discussion likely on hold with Congress on recess until September. DSEI defense conference 9/12-9/15 in London. HWM plant tour/investor meeting 9/20.
Positive on aero:
Commercial aerospace remains one of the best multi-year growth stories in industrials, in our view, with pent-up demand for aircraft driving production higher and ...
2024Q1營收增長18%,營業利潤增長13%,淨利潤增長17%。
目前市盈率56,市盈率TTM略降到51.3,即使按2021年淨利潤高點6.1億計算,市盈率也達到了24.4,估值沒有吸引力。
專欄Today's pre-market stock movers: KSS, TGT, GTLB, SJM and more
• $柯爾百貨(KSS.US)$ +10.4% (Board of Directors enters into three-week exclusive negotiations with $Franchise(FRG.US)$)
• $Gitlab(GTLB.US)$ +8.5% (In reaction to earnings)
• $聯合原生態食品(UNFI.US)$ +6.9% (In reaction to earnings)
• $Dave & Buster's Entertainment(PLAY.US)$ +6.3% (In reaction to earnings)
• $G-III服裝集團(GIII.US)$ +5.6% (In reaction to earnings)
• $HealthEquity(HQY.US)$ +4.2% (In reaction to ea...
專欄Top upgrades and downgrades on 6/7
• $美源伯根(ABC.US)$ : Deutsche Bank Upgrades to Buy from Hold - PT $178 (from $167)
• $Arch Resources(ARCH.US)$ : Jefferies Upgrades to Buy From Hold - PT $225 (from $160)
• $必和必拓(BHP.US)$ : Jefferies Upgrades to Buy From Hold - PT $82 (from $72)
• $Peabody Energy(BTU.US)$ : Jefferies Upgrades to Buy From Hold - PT $36 (from $25)
• $Warrior Met Coal(HCC.US)$ : Jefferies Upgrades to Buy From Hold - PT $50 (from $36)
• $自由全球-A(LBTYA.US)$ : Berenbe...
專欄Today's pre-market stock movers: NIO, DASH, KSS, DE and more
• $Deckers Outdoor(DECK.US)$ +14.6% (In reaction to earnings)
• $Palo Alto Networks(PANW.US)$ +12.3% (In reaction to earnings)
• $ChromaDex(CDXC.US)$ +10.2% (to launch commercial joint venture in mainland China)
• $蔚來(NIO.US)$ +8% (officially listed on the main board of the Singapore Exchange)
• $Allakos(ALLK.US)$ +6% (files for $250 mln common stock offering)
• $CrowdStrike(CRWD.US)$ +5.1% (in sympathy with strong PANW ea...
專欄Today's pre-market stock movers: DAL, JPM, NSTG, ATRS and more
•$Antares Pharma(ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
•$Sierra Oncology(SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
•$Amryt Pharma(AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
•$BriaCell Therapeutics(BCTX.US)$ +6% (presents development details of...
暫無評論